Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol

UMMS Affiliation

UMass Memorial Medical Center

Publication Date


Document Type



Antineoplastic Agents; Colorectal Neoplasms; Desensitization, Immunologic; Dose-Response Relationship, Drug; Drug Hypersensitivity; Female; Humans; Infusions, Intravenous; Middle Aged; Organoplatinum Compounds; effects


Life Sciences | Medicine and Health Sciences


Oxaliplatin (Eloxatin; Sanofi-Synthelabo Inc.; New York, NY) is a third-generation platinum agent indicated for the treatment of colorectal cancer. Severe hypersensitivity reactions to oxaliplatin rarely occur; however, they do represent a threat to the small number of patients that are occasionally affected. We developed a desensitization protocol and successfully applied it to a patient with severe, grade 3, hypersensitivity to oxaliplatin. For patients who have mild sensitivity to oxaliplatin, slowing the run rate down and giving an antihistamine and/or a steroid usually suffice. Desensitization will help to provide the small number of patients who experience severe hypersensitivity reactions with the ability to further receive an effective therapy for their colorectal cancer. The desensitization protocol is described in detail.

DOI of Published Version



Oncologist. 2004;9(5):546-9. Link to article on publisher's site

Journal/Book/Conference Title

The oncologist

Related Resources

Link to Article in PubMed

PubMed ID